[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632312":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":26,"locations":11,"responsibleParty":35,"collaborators":11,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":11,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":11},{"fullName":5,"class":6},"Shenzhen People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral administration of inactive Lactobacillus reuteri group","SHAM_COMPARATOR",null,[13],"Biological: Oral administration of inactive Lactobacillus reuteri group",{"label":15,"type":16,"description":11,"interventionNames":17},"Oral Lactobacillus reuteri group","EXPERIMENTAL",[18],"Biological: Oral Lactobacillus reuteri group",[20,24],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","1×10\\^11 CFU of inactive Lactobacillus reuteri was given orally once daily for one month",[15],{"type":21,"name":9,"description":22,"armGroupLabels":25,"otherNames":11},[9],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Jianglin Zhang","CONTACT","+86 13873143466","zhang.jianglin@szhospital.com",{"name":33,"role":29,"phone":34,"phoneExt":11,"email":11},"Changzhou Li","+86 17827062716",{"type":36,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632312","oral-lactobacillus-reuteri-for-skin-barrier-dysfunction-in-obesity-100632312",false,"NCT07512050","Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity","A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Oral Lactobacillus Reuteri in Treating Skin Barrier Function Impairment Caused by Obesity.","Inclusion Criteria:\n\n* 1\\. Meets 2020 WHO BMI classification:\n* a. Normal weight (18.5-24.9 kg\u002Fm²)\n* b. Overweight (25-29.9 kg\u002Fm²)\n* c. Obesity (≥30 kg\u002Fm²)\n* 2\\. Presence of skin barrier impairment (e.g., dryness, erythema, desquamation, or itching)\n* 3\\. Age 18-40 years\n* 4\\. Generally good health (no active systemic diseases)\n* 5\\. Able and willing to provide written informed consent\n* 6\\. No use of oral\u002Ftopical medications or probiotics within 6 months prior\n* 7\\. No active skin disease or traumatic skin lesions\n\nExclusion Criteria:\n\n* 1\\. Known allergy or hypersensitivity to probiotics, placebo, or investigational product\n* 2\\. Active skin disease (e.g., psoriasis, eczema, infection) requiring treatment\n* 3\\. Severe medical conditions:\n* a. Cardiopulmonary disease (NYHA class III\u002FIV)\n* b. Uncontrolled diabetes (HbA1c \\>9%)\n* c. Autoimmune disorders\n* 4\\. Pregnant or breastfeeding women\n* 5\\. Any condition that may interfere with protocol compliance (per investigator judgement), including:\n* a. Inability to understand study procedures\n* b. History of poor clinical trial adherence\n* 6\\. Concurrent participation in other interventional trials",true,"ALL","18 Years","40 Years",{"count":49,"type":50},140,"ESTIMATED","INTERVENTIONAL",[53],"NA","This clinical trial aims to evaluate the safety and efficacy of oral Lactobacillus reuteri supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with a BMI ≥30. The study focuses on the following questions:\n\nCan oral Lactobacillus reuteri supplementation reduce skin barrier damage (measured by transepidermal water loss\u002FTEWL) in obese participants? Does modulation of gut microbiota with Lactobacillus reuteri impact skin barrier function and systemic inflammation?\n\nResearchers will compare outcomes across two groups:\n\nIntervention Group (Obese): Oral Lactobacillus reuteri capsules. Placebo Control Group (Obese): Oral inactive (heat-killed) Lactobacillus reuteri.\n\nParticipant Procedures:\n\nTake daily oral capsules (Lactobacillus reuteri or inactive strain) for 4 weeks.\n\nUndergo non-invasive skin testing (TEWL measurements) at baseline and study completion.\n\nProvide stool and samples for analyses. Complete weekly check-ins to report adverse effects (e.g., gastrointestinal discomfort, skin irritation).",[56,57],"Skin Barrier to Water Loss","Microbial Colonization","NOT_YET_RECRUITING","2026-03-31",{"date":61,"type":62},"2026-04-06","ACTUAL",{"date":64,"type":50},"2026-04-10",{"date":66,"type":50},"2026-07-30",{"name":5,"class":6}]